Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

References

1. Fifty Years of X-ray Diffraction, P.P. Ewald, Ed. (A. Oosthoek's Uitgeversmaatschappij, Utrecht, 1962).

2. M. Lambert, Acta Crystallogr. 57 (1), 1–3 (2001).

3. J. Schurz, Colloid Polym. Sci. 273 (10), 994–995 (1995).

4. Small Angle X-ray Scattering, O. Glatter and O. Kratky, Eds. (Academic Press, London, 1982) 4f.

5. H. Schnablegger and Y. Singh, "A Practical Guide to SAXS," (Anton Paar, Graz, Austria, 2006).

6. J. Lake, Acta Crystallogr. 23 (2), 191 (1967).

7. G.R. Strobl, Acta Crystallogr. A 26 (3), 367–375 (1970).

8. M. Soliman, B.J. Jungnickel, and E. Meister, Acta Crystallogr., A, Found. 54 (5), 675–681 (1998).

9. C. Jeffries et al., J. Mol. Biol. 377 (4), 1186–1199 (2008).

10. H. Schnablegger, "Is Smearing An Issue?" (Anton Paar Graz, Austria, 2007).

11. M. Muthukumar, C.K. Ober, and E.L. Thomas, Science 277 (5330), 1225–1232 (1997).

12. G.M. Whitesides, J.P. Mathias, and C.T. Seto, Science 254 (5036), 1312–1319 (1991).

13. G.M. Whitesides and B. Crzybowski, Science 295 (5552), 2418–2421 (2002).

14. A.M. Edwards et al., Nat. Struct. Biol. 7 (11), 970–972 (2000).

15. R.F. Fischetti et al., J. Synchrotron Radiat. 10 (5), 398–404 (2003).

16. M. Hirai et al., J. Synchrotron Radiat. 9 (4), 202–205 (2002).

17. D.M. Tiede, R. Zhang, and S. Seifert, Biochemistry 41, 6605–6614 (2002).

18. R. Zhang, P. Thiyagarajan, and D.M. Tiede, J. Appl. Crystallogr. 33 (3), 565–568 (2000).

19. D.I. Svergun and M.H.J. Koch, Rep. Prog. Phys. 66 (10), 1735–1782 (2003).

20. J. Trewhella and J.K. Krueger, Methods Mol. Biol. 173, 137–159 (2002).

21. P. Chacon et al., Biophys. J. 74 (6), 2760–2775 (1998).

22. P. Chacon et al., J. Mol. Biol. 299 (5), 1289–1302 (2000).

23. D. Svergun, Biophys. J. 76 (6), 2879–2886 (1999), erratum in 77, (5), 2896–2896 (1999).

24. G. Fritz, A. Bergmann, and O. Glatter, J. Chem. Phys. 113 (21), 9733–9740 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here